Zenas BioPharma Presents P-II (MoonStone) Trial Data on Obexelimab in Relapsing Multiple Sclerosis (RMS) at ACTRIMS Forum 2026

Shots:The P-II trial of obexelimab (250mg, SC, QW) vs PBO in RMS, met its 1EP with a 95% relative reduction in cumulative new Gd-enhancing T1 lesions over wks. 8 & 12, with near-complete suppression by wk. 8 sustained through wk. 12.Adjusted mean new lesions was 0.01 vs 0.23, only 2 vs 19 total…

ByRidhi RastogiFebruary 10, 2026

NEWS

Zenas BioPharma Enters a ~$300M Funding Agreement with Royalty Pharma to Support Obexelimab Development

Shots:Zenas BioPharma has entered into an agreement with Royalty Pharma granting it royalty rights on the future sales of obexelimabAs per the deal, Zenas will receive ~$300M, consisting of a $75M upfront & 3 additional $75M each in milestones tied to P-III (INDIGO) trial achievement & FDA approvals in IgG4-RD & SLE, while Royalty Pharma…

ByRidhi RastogiSeptember 4, 2025

NEWS

Genentech Reports P-II (FENopta) Trial Data of Fenebrutinib for Relapsing Multiple Sclerosis (RMS)

Shots:Genentech has reported 96wk. data from P-II (FENopta) trial assessing fenebrutinib vs PBO for 12wks. in 109 RMS pts (18-55yrs.); 99 pts then opted for a 192wk. OLE study, with 93 remaining after 96wks.OLE study showed sustained efficacy over 96wks. with a low ARR of 0.06, no disability progression (per EDSS) & no…

ByRidhi RastogiMay 30, 2025

Zenas BioPharma Presents P-II (MoonStone) Trial Data on Obexelimab in Relapsing Multiple Sclerosis (RMS) at ACTRIMS Forum 2026

Zenas BioPharma Enters a ~$300M Funding Agreement with Royalty Pharma to Support Obexelimab Development

Genentech Reports P-II (FENopta) Trial Data of Fenebrutinib for Relapsing Multiple Sclerosis (RMS)

Contact US

FOLLOW US